Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 02, 2024

SELL
$21.16 - $30.8 $78,461 - $114,206
-3,708 Reduced 85.22%
643 $19,000
Q3 2023

Nov 01, 2023

SELL
$21.23 - $24.28 $8,237 - $9,420
-388 Reduced 8.19%
4,351 $97,000
Q2 2023

Aug 04, 2023

SELL
$21.06 - $24.0 $268,388 - $305,856
-12,744 Reduced 72.89%
4,739 $101,000
Q1 2023

Apr 27, 2023

BUY
$23.0 - $29.88 $402,109 - $522,392
17,483 New
17,483 $419,000
Q2 2021

Aug 12, 2021

SELL
$21.74 - $25.28 $32,849 - $38,198
-1,511 Reduced 85.9%
248 $5,000
Q1 2021

Apr 26, 2021

BUY
$19.25 - $26.1 $33,860 - $45,909
1,759 New
1,759 $41,000
Q3 2020

Oct 14, 2020

SELL
$15.78 - $20.82 $6,501 - $8,577
-412 Closed
0 $0
Q2 2020

Jul 13, 2020

BUY
$15.49 - $23.51 $6,381 - $9,686
412 New
412 $7,000
Q1 2020

Apr 29, 2020

SELL
$13.89 - $25.45 $24,904 - $45,631
-1,793 Closed
0 $0
Q4 2019

Feb 05, 2020

BUY
$10.7 - $22.24 $11,705 - $24,330
1,094 Added 156.51%
1,793 $36,000
Q3 2019

Oct 15, 2019

SELL
$10.16 - $13.28 $16,804 - $21,965
-1,654 Reduced 70.29%
699 $8,000
Q2 2019

Jul 26, 2019

BUY
$10.62 - $16.59 $22,493 - $35,137
2,118 Added 901.28%
2,353 $30,000
Q1 2019

Apr 18, 2019

BUY
$13.58 - $18.72 $3,191 - $4,399
235 New
235 $0
Q3 2018

Oct 23, 2018

SELL
$14.16 - $24.3 $8,382 - $14,385
-592 Closed
0 $0
Q2 2018

Jul 30, 2018

SELL
$21.79 - $28.29 $17,540 - $22,773
-805 Reduced 57.62%
592 $14,000
Q1 2018

Apr 26, 2018

SELL
$18.15 - $29.21 $40,202 - $64,700
-2,215 Reduced 61.32%
1,397 $35,000
Q4 2017

Jan 10, 2018

BUY
$9.3 - $19.14 $31,201 - $64,214
3,355 Added 1305.45%
3,612 $66,000
Q3 2017

Oct 25, 2017

BUY
$9.15 - $11.97 $2,351 - $3,076
257
257 $2,000

Others Institutions Holding COLL

About COLLEGIUM PHARMACEUTICAL, INC


  • Ticker COLL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 34,126,200
  • Market Cap $1.12B
  • Description
  • Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...
More about COLL
Track This Portfolio

Track Simplex Trading, LLC Portfolio

Follow Simplex Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.